Is The Cannabis Market Ready For Lab-Grown Cannabinoids? – Benzinga

Natan Ponieman in a recent article “Is The Cannabis Market Ready For Lab-Grown Cannabinoids?” shared the importance of Lab-Grown cannabinoids. Maxim Mikheev and Dennis O’Neill of Biomedican narrated our continuous fermentation approach toward the production of cannabinoids. The disruptive ability of plant produced THC and CBD demands rare cannabinoids like CBG, CBN, THCV, and THCA. Scientists have developed biosynthesis to yield these lesser-known compounds.

Natan mentioned Biomedican’s advanced approach that involves the use of a genetically-modified, proprietary version of yeast to produce cannabinoids without the need for cannabis plants. This biosynthesis technique is less worrisome than they grow, harvest, extract, and purify technique. By employing GMO-yeast, a pure, 99% pharmaceutical grade, organic, and GMO-free product is obtained.

Rare cannabinoids are booming the market because these cannabinoids will be a vital part of the research and therapeutic interest in the future. One of the rare cannabinoids, CBG, has a higher affinity to the endocannabinoid system receptors thus used for neuroprotective, anti-inflammatory, and analgesic effects. Similarly, CBN can kick CBD off the throne owing to its sedative and anti-convulsant property.

The cannabis plant can produce up to 30% THC or CBD. In contrast, the rare cannabinoids are found in much smaller concentrations but are very expensive. According to Dennis O’Neill, this trace concentration is not commercially viable to produce less prevalent cannabinoids via cultivation. O’Neill said that biosynthesized cannabinoids are much more cost-effective than those extracted from the plant material and Biomedican can produce these rare cannabinoids for less than $1 a gram by using 90% less natural resources and energy. Biosynthesis can also avoid unpredictable events like wildfires and other environmental catastrophes.

Natan explained the controversy about the quality of synthetic cannabinoids. Though biosynthetic cannabinoids are safer, contaminant-free, and produce a consistent product, yet these are considered compounds that are unable to replace conventional cannabis culture. But it’s a fact that these biosynthetic cannabinoids can produce cheaper formulation.

Various cannabinoids are under research. The addition of these rare compounds into commercial products can significantly enhance product efficacy. Biomedican has two products that are ready for large-scale production within nine months and we are expecting to sell bulk cannabinoids to the nutraceutical, cosmetic, and pet care industries.

Biomedican is aiming to provide the world with better, cheaper, and consistent cannabinoids with its concept of continuous fermentation. We invite our readers to learn about our novel biosynthetic method from our website.

Saba IqbalAuthor posts

Dr. Saba Iqbal is a contributing writer for BioMedican. She's a clinical pharmacist turned writer. Dr. Saba's education includes a doctoral degree in pharmacy (Pharm D) from the University of Sargodha, Pakistan. In search of a career that would take advantage of her medical and pharmaceutical skills, Dr. Saba found medical writing – a career path a few medical students consider. In her journey "from a medical bench to pen," she has worked with several startups for many years managing content on biotech products, pharmaceuticals, drugs, devices, and techniques. While keeping up with the latest trends in medical writing, she aims to use her writing skills to clearly communicate complex scientific, medical, and health information to the potential investor and general audience.

Comments are disabled.